[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital de Granollers\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":147},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,67,98,124],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100630072","optimizing-the-diagnostic-journey-in-interstitial-lung-disease-the-optimize-ild-1-trial-100630072",false,"NCT07482917","Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial","OPTIMIZE-ILD-1: A Randomized, Pragmatic, Parallel-Group Trial Evaluating the Impact of an Optimized Diagnostic Circuit on Time to Diagnosis in Patients With Suspected Interstitial Lung Disease","OPTIMIZE-ILD-1","Inclusion Criteria:\n\n* Age 18 years or older.\n* Referral for suspected or undiagnosed interstitial lung disease (ILD).\n* At least one of the following:\n\n  * A finding suggestive of ILD (such as reticulation, ground-glass opacities, traction bronchiectasis or honeycombing) not attributable to another disease, on a CT available at referral that includes the lung parenchyma, regardless of its indication; or\n  * Persistent or progressive shortness of breath or chronic cough not attributable to another disease, accompanied by at least one of the following: an interstitial or reticular pattern on chest radiograph; reduced forced vital capacity; persistent bibasilar crackles or digital clubbing; a relevant environmental or occupational exposure, autoimmune disease, or suspected drug or radiation toxicity; or a first-degree family history of ILD.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Complete ILD diagnostic work-up already performed (chest CT plus full pulmonary function testing including six-minute walk test plus complete ILD laboratory panel).\n* Established diagnosis of ILD previously assigned by another center or specialist.\n* Clinical instability or acute illness that would prevent reliable completion of diagnostic procedures (e.g., respiratory infection, suspected acute ILD exacerbation, acute heart failure).\n* Acute iatrogenic pneumonitis (drug-, chemotherapy- or radiation-induced) with a clear temporal relationship to the offending agent.\n* Medical, functional, psychiatric or logistical limitations that, in the investigators' opinion, would interfere with the diagnostic process or data collection.\n* Participation in another interventional clinical trial that may alter the frequency or timing of diagnostic procedures.\n* Cognitive impairment that prevents informed consent or completion of study questionnaires.\n* Refusal to participate or to allow the collection or use of clinical data.","ALL","18 Years",{"count":20,"type":21},92,"ESTIMATED","INTERVENTIONAL",[24],"NA","The OPTIMIZE-ILD-1 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated diagnostic pathway on patients with suspected interstitial lung disease (ILD). In routine clinical practice, diagnostic workflows for ILD are frequently fragmented, involving multiple independent appointments that can lead to significant delays and increased burden for patients and caregivers. This study compares the standard diagnostic pathway against an optimized circuit where core diagnostic procedures-such as high-resolution CT, pulmonary function tests, and laboratory panels-are pre-bundled and scheduled within a coordinated and compressed timeframe.\n\nAll eligible patients referred for suspected ILD are included consecutively to ensure a pragmatic, real-world representation of the referral population. The primary objective is to measure the time to diagnostic communication, defined as the duration from randomization to the date the patient is formally informed of the final diagnosis following a multidisciplinary team (MDT) consensus. Secondary objectives include assessing the time to MDT diagnosis, the time to treatment initiation (when clinically indicated), socioeconomic cost-burden, and the environmental carbon footprint of the diagnostic journey. Furthermore, the study evaluates health-related quality of life, psychological distress, and clinical frailty, while exploring factors such as language proficiency as determinants of diagnostic equity. Caregiver-related outcomes, including burden and experience measures, are contingent upon the presence of a primary caregiver and the provision of their independent informed consent.\n\nThe design of this protocol was informed by a patient focus group and is officially endorsed by the 'AIRE' Associació Catalana de Malalts i Trasplantats Pulmonars, ensuring a patient-centered approach that prioritizes the diagnostic journey's efficiency and human impact.",[27,28,29,30,31],"Interstitial Lung Disease (ILD)","Suspected Interstitial Lung Disease","Fibrotic Interstitial Lung Disease","Idiopathic Pulmonary Fibrosis (IPF)","Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)",[33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53],"Interstitial Lung Disease","ILD","Suspected ILD","Pulmonary Fibrosis","Idiopathic Pulmonary Fibrosis","Connective Tissue Disease-ILD","IPF","Diagnostic Pathway","Diagnostic Delay","Multidisciplinary Discussion","One-Day ILD Clinic","Time to Diagnosis","Time to Treatment Initiation","Organizational Intervention","Health Services Research","Diagnostic Workflow Optimization","Patient Experience","Quality of Life","Pulmonary Function Tests","High-Resolution CT","Carbon Footprint","RECRUITING","2026-06-30",{"date":57,"type":58},"2026-07-02","ACTUAL",{"date":60,"type":58},"2026-03-09",{"date":62,"type":21},"2028-03-01",{"name":64,"class":65},"Hospital de Granollers","OTHER",1,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":96,"leadSponsor":97,"locationsCount":66},"100630325","optimizing-the-follow-up-journey-in-interstitial-lung-disease-the-optimize-ild-2-trial-100630325","NCT07486206","Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial","OPTIMIZE-ILD-2: A Randomized, Pragmatic, Parallel-Group Trial Evaluating the Impact of an Optimized Coordinated Follow-Up Circuit on Time Burden in Patients With Interstitial Lung Disease","OPTIMIZE-ILD-2","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Established diagnosis of interstitial lung disease (ILD).\n* Currently receiving antifibrotic therapy, immunosuppressive therapy, or both, as part of routine ILD care.\n* Under active follow-up at the participating ILD center.\n* Able to attend the required follow-up procedures included in the study visit.\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Inability to complete the coordinated follow-up visit for non-medical reasons (e.g., logistical impossibility).\n* Clinical instability or acute illness interfering with planned follow-up procedures (such as respiratory infection, suspected ILD exacerbation, acute heart failure, or other acute conditions).\n* Participation in another interventional clinical trial that may alter visit frequency or follow-up structure.\n* Cognitive impairment preventing informed consent or completion of questionnaires.\n* Patient refusal to participate or refusal to allow data collection.",{"count":76,"type":21},152,[24],"The OPTIMIZE-ILD-2 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated follow-up pathway on patients with established interstitial lung disease (ILD). In routine clinical practice, follow-up workflows for ILD are frequently fragmented, requiring multiple hospital visits for pulmonary function tests, laboratory analysis, treatment administration, and consultations with various specialists, which increases the burden for both patients and caregivers. This study compares the standard follow-up care against an optimized circuit where all routine monitoring procedures and interdisciplinary consultations are pre-bundled and scheduled within a single, coordinated hospital visit.\n\nAll eligible patients under active ILD follow-up are included consecutively to ensure a pragmatic, real-world representation of the treated ILD population. The primary objective is to measure the total follow-up time burden, defined as the total home-to-home time required to complete the follow-up circuit. As a cross-sectional assessment within a longitudinal context, secondary objectives include assessing socioeconomic cost-burden, the environmental carbon footprint of the follow-up journey, health-related quality of life, and clinical frailty. Caregiver-related outcomes, including burden and experience measures, are contingent upon the presence of a primary caregiver and the provision of their independent informed consent.\n\nThe design of this protocol was informed by a patient focus group and is officially endorsed by the 'AIRE' Associació Catalana de Malalts i Trasplantats Pulmonars, ensuring a patient-centered approach that prioritizes follow-up efficiency and human impact.",[27,29,30,80,31],"Progressive Pulmonary Fibrosis",[33,34,36,37,80,82,83,84,85,86,87,88,89,43,47,90,46,51,50,49,53,91],"CTD-ILD","Fibrotic ILD","Antifibrotic Therapy","Immunosuppressive Therapy","Follow-Up Pathway","Follow-Up Care Coordination","Time Burden","Home-to-Home Time Burden","Patient-Centered Follow-Up","Multidisciplinary Care","2026-04-06",{"date":94,"type":58},"2026-04-09",{"date":60,"type":58},{"date":62,"type":21},{"name":64,"class":65},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":66},"100602987","ai-algorithm-for-surveillance-of-deep-surgical-site-infections-after-elective-colorectal-surgery-100602987","NCT07130656","AI Algorithm for Surveillance of Deep Surgical Site Infections After Elective Colorectal Surgery.","A Novel AI Algorithm With Enhanced Accuracy for Surveillance of Deep Surgical Site Infections After Elective Colorectal Surgery. A Diagnostic Accuracy Study.","Infect-IA-2","Inclusion Criteria:\n\n* Elective colorectal resection\n\nExclusion Criteria:\n\n* Emergency surgery\n* Infection present at operation\n* Previous intestinal stoma",{"count":107,"type":21},1200,"OBSERVATIONAL","Epidemiological surveillance is one of the eight core components of the World Health Organization Infection Prevention and Control Programmes. These include surveillance programmes for surgical site infection (SSI).\n\nAt present, for SSI surveillance, infection control teams perform a manual time-consuming work, which could make a transition to automated surveillance leveraging the new information technology.\n\nThe aim of this study was to evaluate the performance of a novel algorithm to detect SSI in a cohort of elective colorectal surgery patients who have been previously screened within a nationwide healthcare-associated infection surveillance system.",[111],"Surgical Site Infection",[111,113,114,115],"Surveillance","Articicial inteligence","Algorithms","2025-08-19",{"date":118,"type":58},"2025-08-24",{"date":120,"type":58},"2025-01-15",{"date":122,"type":21},"2025-10-30",{"name":64,"class":65},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":133,"conditions":134,"keywords":135,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":144,"leadSponsor":146,"locationsCount":66},"100564224","chatgpt-4-for-surgical-site-infection-detection-from-electronic-health-records-after-colorectal-surgery-100564224","NCT06626399","ChatGPT-4 for Surgical Site Infection Detection From Electronic Health Records After Colorectal Surgery.","Evaluation of ChatGPT-4 for the Detection of Surgical Site Infections From Electronic Health Records After Colorectal Surgery: A Diagnostic Accuracy Study.","Infect-IA-3",{"count":132,"type":21},1100,"Epidemiological surveillance is one of the eight core components of the World Health Organization Infection Prevention and Control Programmes. These include surveillance programmes for surgical site infection (SSI).\n\nAt present, for SSI surveillance, infection control teams perform a manual time-consuming work, which could make a transition to automated surveillance leveraging the new information technology.\n\nThis study aimed to evaluate the ability of ChatGPT-4o to detect surgical site infection at the three anatomical levels.",[111],[136,113,137,138,139],"Surgical site infection","ChatGPT","Natural language processing","Artificial inteligence","2025-08-12",{"date":142,"type":58},"2025-08-15",{"date":120,"type":58},{"date":145,"type":21},"2025-11-30",{"name":64,"class":65},""]